Published November 2021 | Version v1
Journal article

Characterization of a custom-made 241Am alpha-source for radiobiological studies

  • 1. The Patrick G Johnston Centre for Cancer Research, Queen's University of Belfast, 97 Lisburn Road, Belfast, BT9 7AE (United Kingdom)

Description

Highlights: • Characterization of a compact 241Am alpha-source. • Improvement of alpha particle energy spectrum with a 3D printed collimator. • Proven feasibility of a low-cost alpha-irradiation setup for in vitro assays. • Alpha particle RBE for 10% survival in PC-3 is 3.66. A compact in-house alpha particle source has been developed and fully characterized. The irradiation source is a large area, 25 cm2, 5.4 MeV average energy 241Am source, above which a Mylar dish containing a monolayer of target cells can be placed at defined positions. The source uniformity, flux, particle energy and dose rate were determined experimentally. The dose rate to the nucleus at the closest position was 1.57 Gy/min. Furthermore, a 3D printed collimator was tested and found to improve the uniformity of the energy spectra of particles reaching the target. For validation, prostate PC-3 cells were irradiated in our experimental setup with absorbed doses up to 2 Gy and for reference compared with cells irradiated with conventional X-rays with doses up to 8 Gy. The Relative Biological Effectiveness for alpha particles at 10% survival was 3.66± 0.40 agreeing with previously published data. Data presented here show the feasibility of utilising a low-cost alpha-irradiation source for accurate in vitro assays to better understand the radiobiological effects of high LET alpha particles.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.apradiso.2021.109931

Additional details

Identifiers

DOI
10.1016/j.apradiso.2021.109931;
PII
S0969804321003286;

Publishing Information

Journal Title
Applied Radiation and Isotopes
Journal Volume
177
Journal Page Range
vp.
ISSN
0969-8043
CODEN
ARISEF

Optional Information

Copyright
Copyright (c) 2021 Elsevier Ltd. All rights reserved.